Equities

PureTech Health PLC

PureTech Health PLC

Actions
  • Price (USD)4.00
  • Today's Change0.25 / 6.67%
  • Shares traded3.00k
  • 1 Year change33.33%
  • Beta1.0388
Data delayed at least 15 minutes, as of Jul 06 2020 20:45 BST.
More ▼

Profile data is unavailable for this security.

About the company

PureTech Health PLC is a clinical stage biotechnology company. The Company is engaged in discovering, developing and commercializing medicines for diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders, and inflammatory and immunological diseases, among others. Its segments include Internal and Affiliates. The Internal division is focused on advancing a pipeline fueled by discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. The Affiliates segment is comprised of the programs within its Affiliates division that are consolidated operational subsidiaries that have research and development programs. Its wholly owned pipeline includes various candidates, such as LYT-100, LYT-200, LYT-210, Lymphatic Targeting Chemistry Platform, Milk Exosome Platform and Meningeal Lymphatics Platform.

  • Revenue in GBP (TTM)7.86m
  • Net income in GBP337.37m
  • Incorporated2015
  • Employees300.00
  • Location
    PureTech Health PLC501 Boylston St Ste 6102BOSTON 02116-3769United StatesUSA
  • Phone+1 (617) 482-2333
  • Fax+1 (617) 482-3337
  • Websitehttp://puretechhealth.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PRTC:LSE since
announced
Transaction
value
Ariya Therapeutics IncDeal completed02 Oct 201902 Oct 2019Deal completed7.45%666.98m
Data delayed at least 20 minutes, as of Jul 06 2020 16:35 BST.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.